Clinical-stage company developing gene therapies for severe genetic and rare diseases.
H.R. 1892, Bipartisan Budget Act of 2018 and issues related to Medicare reimbursement for prescription drugs; monitored H.R. 1625, Consolidated Appropriations Act of 2018 and issues related to drug pricing; issue related to value-based pricing. Issues related to novel therapies for rare pediatric populations; issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.
MMM - Medicare/Medicaid HCR - Health Issues
136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 139 - Natl Institutes of Health (NIH) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 139 - Natl Institutes of Health (NIH) 1 - SENATE
THE NICKLES GROUP, LLC
601 13th St. NW, Suite 250 N, Washington, DC, 20005, US
EMILY PORTER STACEY HUGHES KATHERINE RAAB STACEY HUGHES EMILY PORTER KATHERINE RAAB